AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8494559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exposure to 45-Hz magnetic fields
Number of subjects: 20
Study 8494559 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 20
Study 8494559 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exposure first
Number of subjects: 20
Study 3567002 — intervention group
Group type: EXPERIMENTAL
Intervention: Leicester Micropalliator (1 mg h-1 mandatory background infusion + 2 mg i.v. on-demand bolus doses of morphine)
Number of subjects: 0
Study 3567002 — intervention group
Group type: COMPARATOR
Intervention: Cardiff Palliator (only 2 mg i.v. on-demand bolus doses of morphine)
Number of subjects: 0
Study 30993537 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 99
Study 30993537 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine (group L)
Number of subjects: 99
Study 30993537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% benzydamine hydrochloride (group B)
Number of subjects: 99
Study 27476818 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisolone 15 mg/day)
Number of subjects: 120
Study 27476818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26179201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (20 mg oral once a day) with cisplatin (25 mg/m2) and gemcitabine (1000 mg/m2) chemotherapy
Number of subjects: 124
Study 26179201 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cisplatin (25 mg/m2) and gemcitabine (1000 mg/m2) chemotherapy
Number of subjects: 124
Study 23418430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HT) regimen continued for approximately 2 years (Mean = 1.93 years)
Number of subjects: 63
Study 23418430 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (HT) regimen discontinued for approximately 2 years (Mean = 1.93 years)
Number of subjects: 63
Study 23418430 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-carrier women on hormone replacement therapy (HT)
Number of subjects: 63
Study 23418430 — intervention group
Group type: COMPARATOR
Intervention: Non-carrier women off hormone replacement therapy (HT)
Number of subjects: 63
Study 21372447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 37
Study 21372447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (9 months)
Number of subjects: 37
Study 21372447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 37
Study 19927226 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/day
Number of subjects: 0
Study 19927226 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 17223424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) alone
Number of subjects: 1303
Study 17223424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with implantable cardioverter-defibrillator (ICD) backup
Number of subjects: 1303
Study 17223424 — intervention group
Group type: COMPARATOR
Intervention: Control group (CRT alone)
Number of subjects: 1303
Study 14761173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealant program
Number of subjects: 2
Study 14761173 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 11495397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/day)
Number of subjects: 41
Study 11495397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11495397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 41
Study 9385472 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1-blockade (5 mg prazosin in preceding 24 h)
Number of subjects: 24
Study 9385472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9385472 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1-blockade
Number of subjects: 24
Study 7955188 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability tested with two shocks on the peak or the up‐slope of the T wave (protocol 1)
Number of subjects: 77
Study 7955188 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability tested with three shocks delivered at 0, 20, and 40 milliseconds before the peak of the T wave (protocol 2)
Number of subjects: 77
Study 7955188 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability in 45 of the 60 patients
Number of subjects: 77
Study 7955188 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability in 51 of the 60 patients
Number of subjects: 77
Study 7955188 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability > 15 J
Number of subjects: 77
Study 3322532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (40 mg)
Number of subjects: 7
Study 3322532 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aspirin (324 mg)
Number of subjects: 7
Study 3322532 — intervention group
Group type: COMPARATOR
Intervention: Control (resting state and pacing stress)
Number of subjects: 7
Study 30919083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried food consumption 1-3 times/week
Number of subjects: 18941
Study 30919083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried food consumption ≥ 4 times/week
Number of subjects: 18941
Study 30919083 — intervention group
Group type: COMPARATOR
Intervention: Fried food consumption < 1 time/week (reference group)
Number of subjects: 18941
Study 29386371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Runnings app-based hot beverage scald prevention campaign
Number of subjects: 498
Study 29386371 — intervention group
Group type: EXPERIMENTAL
Intervention: First aid training in the past year
Number of subjects: 498
Study 29386371 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 498
Study 28638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Su Jok
Number of subjects: 84
Study 28638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 84
Study 28638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 84
Study 28638026 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 26320402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol 5/5 μg
Number of subjects: 0
Study 26320402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol 2.5/5 μg
Number of subjects: 0
Study 26320402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26320402 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 5 μg
Number of subjects: 0
Study 23837770 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling cues exposure
Number of subjects: 250
Study 23837770 — intervention group
Group type: COMPARATOR
Intervention: Non-gambling cues exposure
Number of subjects: 250
Study 21652735 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline (2 mg/day)
Number of subjects: 218
Study 21652735 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 218
Study 19210040 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational use of cocaine
Number of subjects: 0
Study 19210040 — intervention group
Group type: COMPARATOR
Intervention: Cocaine-free matched sample
Number of subjects: 0
Study 16963680 — intervention group
Group type: EXPERIMENTAL
Intervention: BPV-S/T
Number of subjects: 10
Study 16963680 — intervention group
Group type: EXPERIMENTAL
Intervention: BPV-S/T-AVAPS
Number of subjects: 10
Study 12560149 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg per day for 3 days)
Number of subjects: 78
Study 12560149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (40 mg/kg per day for 10 days)
Number of subjects: 78
Study 11099319 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy external-beam radiotherapy
Number of subjects: 305
Study 11099319 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy external-beam radiotherapy
Number of subjects: 305
Study 11099319 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy external-beam radiotherapy and 78 Gy external-beam radiotherapy
Number of subjects: 305
Study 8816674 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed work team structure
Number of subjects: 0
Study 1349376 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme‐potentiated desensitisation (EPD) - three doses of EPD (beta‐glucuronidase and small quantities of food antigens) intradermally at two‐monthly intervals.
Number of subjects: 40
Study 1349376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (buffer only)
Number of subjects: 40
Study 3926254 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% fat parenteral diet
Number of subjects: 41
Study 3926254 — intervention group
Group type: COMPARATOR
Intervention: 0% fat parenteral diet
Number of subjects: 41
Study 3926254 — intervention group
Group type: COMPARATOR
Intervention: 50% fat parenteral diet
Number of subjects: 41
Study 30745388 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole
Number of subjects: 0
Study 30745388 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg oxantel pamoate
Number of subjects: 0
Study 30745388 — intervention group
Group type: COMPARATOR
Intervention: DBS and wet samples
Number of subjects: 0
Study 30745388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitra microsampling device
Number of subjects: 0
Study 30325931 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based device-specific videos
Number of subjects: 159
Study 30325931 — intervention group
Group type: COMPARATOR
Intervention: Standard personal instruction
Number of subjects: 159
Study 27108892 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 39
Study 27108892 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 39
Study 24658367 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred therapy
Number of subjects: 269
Study 23018695 — intervention group
Group type: EXPERIMENTAL
Intervention: Prineo Skin Closure System
Number of subjects: 83
Study 23018695 — intervention group
Group type: COMPARATOR
Intervention: Intraderma sutures
Number of subjects: 83
Study 20414546 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/day of L-carnitine for 30 days
Number of subjects: 21
Study 20414546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 30 days
Number of subjects: 21
Study 20414546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) under resting conditions
Number of subjects: 21
Study 18341600 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% CHX solution
Number of subjects: 18
Study 18341600 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 18
Study 15817862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (3.86 g/d sodium)
Number of subjects: 35
Study 15817862 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (1.30 g/d sodium)
Number of subjects: 35
Study 15817862 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium retention in black girls
Number of subjects: 35
Study 12430737 — intervention group
Group type: COMPARATOR
Intervention: UVB only
Number of subjects: 27
Study 12430737 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB combined with vitamin B12 and folic acid
Number of subjects: 27
Study 11065040 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly drug-in-adhesive (DIA) patches
Number of subjects: 35
Study 11065040 — intervention group
Group type: COMPARATOR
Intervention: Reservoir patch
Number of subjects: 35
Study 11065040 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patches
Number of subjects: 35
Study 11065040 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal treatment
Number of subjects: 35
Study 8871900 — intervention group
Group type: EXPERIMENTAL
Intervention: PWV and heart rate variability indices in patients with diabetic neuropathy
Number of subjects: 227
Study 8871900 — intervention group
Group type: COMPARATOR
Intervention: PWV and heart rate variability indices in healthy subjects
Number of subjects: 227
Study 1361795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal imipenem/cilastatin (2 gm daily)
Number of subjects: 41
Study 1361795 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal netilmicin and vancomycin (500 and 60-100 mg daily respectively)
Number of subjects: 41
Study 6235604 — intervention group
Group type: EXPERIMENTAL
Intervention: Impromidine with mepyramine maleate
Number of subjects: 0
Study 6235604 — intervention group
Group type: COMPARATOR
Intervention: Impromidine without mepyramine maleate
Number of subjects: 0
Study 31679521 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy (4 sessions, monthly intervals)
Number of subjects: 120
Study 31679521 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (weekly for 4 sessions)
Number of subjects: 120
Study 31679521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (prolotherapy + physiotherapy)
Number of subjects: 120
Study 30309995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil for 12 weeks
Number of subjects: 340
Study 30309995 — intervention group
Group type: COMPARATOR
Intervention: Prednisone for 12 weeks
Number of subjects: 340
Study 27220527 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy + Kinesio Taping + Exercise (MT + KT + EX)
Number of subjects: 70
Study 27220527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy + Manual Therapy + Kinesio Taping + Exercise (HILT + MT + KT + EX)
Number of subjects: 70
Study 27220527 — intervention group
Group type: COMPARATOR
Intervention: Kinesio Taping + Exercise (KT + EX)
Number of subjects: 70
Study 24554030 — intervention group
Group type: EXPERIMENTAL
Intervention: StomaphyX treatment
Number of subjects: 120
Study 24554030 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 120
Study 22179130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinitol (1,200 mg)
Number of subjects: 66
Study 22179130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 20483969 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention
Number of subjects: 126
Study 20483969 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy and education (Control)
Number of subjects: 126
Study 17715209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine-depleting amino acid mixture
Number of subjects: 100
Study 17715209 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid mixture
Number of subjects: 100
Study 15508014 — intervention group
Group type: EXPERIMENTAL
Intervention: LKFibre diet
Number of subjects: 38
Study 15508014 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 38
Study 11526558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine alone
Number of subjects: 32
Study 11526558 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine alone
Number of subjects: 32
Study 11526558 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine mixed with bupivacaine
Number of subjects: 32
Study 11526558 — intervention group
Group type: COMPARATOR
Intervention: Control (Sterile saline solution)
Number of subjects: 32
Study 9126192 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 or 60 mg/kg ALA preoperatively
Number of subjects: 0
Study 9126192 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of ALA (60 mg/kg)
Number of subjects: 0
Study 8290743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg b.d. for 4 days
Number of subjects: 34
Study 8290743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg o.d. for 4 days
Number of subjects: 34
Study 3306159 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (BCNU 80 mg/M2 I.V. every 4 weeks, actinomycin‐D 0.01 mg/kg, and vincristine 1.0 mg/M2 I.V. every 2 weeks for 6 months)
Number of subjects: 59
Study 3306159 — intervention group
Group type: COMPARATOR
Intervention: Surgical control
Number of subjects: 59
Study 3306159 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 59
Study 2769192 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcomputer tickler system
Number of subjects: 1262
Study 2769192 — intervention group
Group type: COMPARATOR
Intervention: No information regarding previous mammograms printed
Number of subjects: 1262
Study 5555492 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic bacteriuria during pregnancy
Number of subjects: 0
Study 5555492 — intervention group
Group type: COMPARATOR
Intervention: Maternal urinary infection
Number of subjects: 0
Study 30895296 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed haemodynamic optimization (EGDHO) with MAP 85-100 mmHg
Number of subjects: 112
Study 30895296 — intervention group
Group type: COMPARATOR
Intervention: MAP 65 mmHg strategy
Number of subjects: 112
Study 30895296 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed haemodynamic optimization (EGDHO)
Number of subjects: 112
Study 27650995 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50mg)
Number of subjects: 24
Study 27650995 — intervention group
Group type: COMPARATOR
Intervention: SRD
Number of subjects: 24
Study 26066299 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid (FA) supplementation for 3 months
Number of subjects: 0
Study 24140390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent killed whole-cell oral cholera vaccine (two doses, 14 days apart)
Number of subjects: 34968
Study 24140390 — intervention group
Group type: COMPARATOR
Intervention: Heat-killed Escherichia coli K12 placebo
Number of subjects: 34968
Study 21641352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 4133
Study 21641352 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4133
Study 19030772 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (at dinnertime)
Number of subjects: 20
Study 19030772 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) insulin (at bedtime)
Number of subjects: 20
Study 19030772 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus OADs
Number of subjects: 20
Study 19030772 — intervention group
Group type: COMPARATOR
Intervention: NPH plus OADs
Number of subjects: 20
Study 16844265 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restriction
Number of subjects: 3
Study 16844265 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-restriction
Number of subjects: 3
Study 16844265 — intervention group
Group type: COMPARATOR
Intervention: Control (no restriction)
Number of subjects: 3
Study 15564113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer perceptron neural network (MLPNN) trained with Lyapunov exponents as inputs
Number of subjects: 0
Study 11520523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiotocography plus ST analysis (CTG+ST group)
Number of subjects: 4966
Study 11520523 — intervention group
Group type: COMPARATOR
Intervention: Cardiotocography only (CTG group)
Number of subjects: 4966
Study 9118711 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cocaine base (45 mg)
Number of subjects: 0
Study 9118711 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cocaine HCl (0.35 to 0.50 mg/kg)
Number of subjects: 0
Study 9118711 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo (4.5 mg cocaine base)
Number of subjects: 0
Study 9118711 — intervention group
Group type: COMPARATOR
Intervention: IV placebo (saline solution)
Number of subjects: 0
Study 9118711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (inhaled or IV)
Number of subjects: 0
Study 7505979 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA value of 10 ng/mL or less
Number of subjects: 0
Study 7505979 — intervention group
Group type: COMPARATOR
Intervention: Staging radionuclide bone scan
Number of subjects: 0
Study 2941208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of sodium chloride/potassium chloride solution (saline) 6 ml/kg body weight
Number of subjects: 7
Study 2941208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of sodium chloride/potassium chloride solution (saline) 12 ml/kg body weight
Number of subjects: 7
Study 2941208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of sodium chloride/potassium chloride solution (saline) 18 ml/kg body weight
Number of subjects: 7
Study 29135589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tao mask
Number of subjects: 152
Study 26018213 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural
Number of subjects: 17
Study 26018213 — intervention group
Group type: COMPARATOR
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 17
Study 25010300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral vaporization of the prostate (TUVP)
Number of subjects: 88
Study 25010300 — intervention group
Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (TURP)
Number of subjects: 88
Study 22159015 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with POAG (n = 359)
Number of subjects: 2609
Study 22159015 — intervention group
Group type: COMPARATOR
Intervention: Non-POAG eyes (n = 2250)
Number of subjects: 2609
Study 22159015 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes reaching POAG endpoints based on only VF change (n = 74)
Number of subjects: 2609
Study 22159015 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes reaching POAG endpoints based on only optic disc change (n = 158)
Number of subjects: 2609
Study 22159015 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes reaching POAG endpoints for both VF and optic disc change (n = 127)
Number of subjects: 2609
Study 22159015 — intervention group
Group type: COMPARATOR
Intervention: Original OHTS randomization (observe vs. treat)
Number of subjects: 2609
Study 20035818 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybum marianum extract (600 mg/day)
Number of subjects: 35
Study 20035818 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (30 mg/day)
Number of subjects: 35